Takeda (NINLARO)
(https://ninlaro.com) 📸 Data Snapshot: May 30, 2026
Identity & Authority — The Lens
Inspect the JSON-LD. Is there an Organization or Person schema, and does it carry sameAs links to real external profiles (LinkedIn, socials)? Missing schema or no identity declaration signals an anonymous entity.
Identity & Authority
Expert verifiability & Schema depth.
14
Impact Weight: 15 / 100
93% Reputation
Authority is well-established through Takeda’s corporate branding and the presence of MedicalWebPage and Drug schema. A minor gap exists in the Person schema, as individual medical reviewers or experts are not linked to their professional digital footprints (sameAs links). The citations provided, such as Mahindra 2010 and Moreau 2012, are significantly stale relative to the May 2026 system date, being over 10 years old. Despite the lack of recent real-world evidence (RWE) from 2024-2026 in the provided text, the foundational authority of the cited peer-reviewed journals remains high.
There is a strong connection between performance claims and data-driven proof points. The claim that the drug improves the time people live without their disease getting worse is immediately quantified with a 5.9-month survival delta (20.6 vs 14.7). The marketing tone of freedom and independence is strictly tied to the oral delivery mechanism, which is a demonstrated pharmacological fact rather than an abstract benefit. The only disconnect is the focus on Overall Survival on the clinical results page, which admits that the study showed a similar overall length of time as the control, slightly tempering the breakthrough narrative.
Identity & Authority is read from the structured data first: whether the site declares who it is in machine-readable schema, with verifiable identity links. Below is the schema captured per page, then the external proof links that support (or fail to support) that identity.
🔗 Identity & Technical Layer — schema JSON-LD: identity chains, entity gaps
Homepage schema
{
"@context": "http://schema.org",
"@type": "MedicalWebPage",
"audience": "https://health-lifesci.schema.org/Patient",
"specialty": "https://health-lifesci.schema.org/Oncologic",
"url": "https://www.ninlaro.com/",
"headline": "NINLARO® (ixazomib) - Patient Information",
"description": "Learn about the NINLARO® (ixazomib) treatment combination for multiple myeloma that has returned that may help you keep an active lifestyle. See Important Safety Information and Prescribing Information.",
"image": [
{
"@type": "ImageObject",
"name": "NINLARO® (ixazomib) logo",
"contentUrl": "https://www.ninlaro.com/themes/custom/tbsd_sub/logo.svg"
},
{
"@type": "ImageObject",
"name": "Takeda logo.",
"contentUrl": "https://www.ninlaro.com/sites/default/files/2023-02/logo-takeda.svg"
}
],
"mainEntity": [
{
"@type": "WebPageElement",
"name": "How can NINLARO help",
"text": "NINLARO is the first and only oral medication of its kind, a proteasome inhibitor, that may help people when their multiple myeloma comes back. In a study of multiple myeloma patients whose disease had returned after a prior treatment, the combination of NINLARO plus REVLIMID® (lenalidomide) and dexamethasone was shown to improve the time people were able to live with their multiple myeloma without it getting worse by nearly 6 months (20.6 months for the people who took the NINLARO treatment com"
}
],
"speakable": [
{
"@type": "SpeakableSpecification",
"xpath": "/html/body/div[1]/main/div/article/div/div[1]/div/div/header/div/div[1]/div[1]/p/small"
}
],
"potentialAction": [
{
"@type": "ViewAction",
"name": "Ninlaro clinical studies",
"url": "https://www.ninlaro.com/clinical-studies"
},
{
"@type": "ViewAction",
"name": "How Ninlaro works",
"url": "https://www.ninlaro.com/how-it-works"
},
{
"@type": "ViewAction",
"name": "Look at the questions to aks your doctor",
"url": "https://www.ninlaro.com/treatment-questions"
},
{
"@type": "ViewAction",
"name": "Look at your patient videos",
"url": "https://www.ninlaro.com/patient-stories"
},
{
"@type": "ViewAction",
"name": "Look at takeda oncology Here2Assist patient support",
"url": "https://www.ninlaro.com/financial-support"
}
],
"Video": {
"@type": "VideoObject",
"name": "Joe's Multiple Myeloma Journey",
"description": "NINLARO gave the me the ability to say, 'Hey I can still work. I can still travel.' I don't have to be home and in the hospital on these days of the week. I can take my treatment with me and be able to work and have more of a full life from that possibility.",
"thumbnailUrl": "https://cf-images.us-east-1.prod.boltdns.net/v1/static/2574028764001/6ba0cfb0-5af2-4b6e-83f2-65b3d5a9703d/423d939f-3838-4a38-b631-5f147762c7e3/1280x720/match/image.jpg",
"duration": "PT11M13S",
"contentUrl": "https://players.brightcove.net/2574028764001/SykGTiz2b_default/index.html?videoId=6323574500112",
"embedUrl": "https://players.brightcove.net/2574028764001/SykGTiz2b_default/index.html?videoId=6323574500112",
"transcript": "This video features a real patient sharing his experience living with multiple myeloma and being treated with NINLARO®. The information in this video is based on his experience at the time of recording. Given the nature of multiple myeloma, experiences may change over time. This is Joe’s experience while taking NINLARO, and yours may be different. JOE: I've been married for 48 years. We normally are early risers, so we get up anywhere from 5:30 to 6:30 in the morning. We like to exercise as a w"
},
"about": [
{
"@type": "Drug",
"name": "Ninlaro",
"nonProprietaryName": "ixazomib",
"offers": {
"@type": "Offer",
"price": "0",
"priceCurrency": "USD",
"url": "https://www.takedaoncologycopay.com"
},
"image": {
"@type": "ImageObject",
"name": "NINLARO® (ixazomib) logo",
"contentUrl": "https://www.ninlaro.com/images/ninlaro-ixazomib.png"
},
"prescribingInfo": "https://ninlaro.com/prescribing-information.pdf",
"mechanismOfAction": [
"Ixazomib is a reversible proteasome inhibitor. Ixazomib preferentially binds and inhibits the chymotrypsin-like activity of the beta 5 subunit of the 20S proteasome. Ixazomib induced apoptosis of multiple myeloma cell lines in vitro. Ixazomib demonstrated in vitro cytotoxicity against myeloma cells from patients who had relapsed after multiple prior therapies, including bortezomib, lenalidomide, and dexamethasone. The combination of ixazomib and lenalidomide demonstrated synergistic cytotoxic ef"
],
"warning": "[“NINLARO may cause serious side effects, including: Low platelet counts (thrombocytopenia) are common with NINLARO and can sometimes be serious. You may need platelet transfusions if your counts are too low. Tell your healthcare provider if you have any signs of low platelet counts, including bleeding and easy bruising. Stomach and intestinal (gastrointestinal) problems. Diarrhea, constipation, nausea, and vomiting are common with NINLARO and can sometimes be severe. Call your healthcare provid",
"manufacturer": {
"@type": "Corporation",
"name": "Takeda",
"logo": "https://www.ninlaro.com/sites/default/files/2023-02/logo-takeda.svg"
}
}
],
"_truncated": true,
"_original_size": 18103
}
/clinical-studies/
{
"@context": "http://schema.org",
"@type": "MedicalWebPage",
"audience": "https://health-lifesci.schema.org/Patient",
"specialty": "https://health-lifesci.schema.org/Oncologic",
"url": "https://www.ninlaro.com/clinical-studies",
"headline": "Results with NINLARO® (ixazomib)",
"description": "Learn about the results of the NINLARO treatment combination in a clinical study, including how it may help you live longer without your multiple myeloma getting worse. See Important Safety Information and Prescribing Information",
"speakable": {
"@type": "SpeakableSpecification",
"xpath": "/html/body/div[1]/main/div/article/div/div[2]/div/div[2]/div/p/span"
},
"image": [
{
"@type": "ImageObject",
"name": "NINLARO® (ixazomib) logo",
"contentUrl": "https://www.ninlaro.com/themes/custom/tbsd_sub/logo.svg"
},
{
"@type": "ImageObject",
"name": "Takeda logo.",
"contentUrl": "https://www.ninlaro.com/sites/default/files/2023-02/logo-takeda.svg"
},
{
"@type": "ImageObject",
"name": "The NINLARO combination consisting of NINLARO, lenalidomide, and dexamethasone vs a placebo, lenalidomide, and dexamethasone combination.",
"contentUrl": "https://www.ninlaro.com/sites/default/files/2022-12/ninlaro-and-placebo-combination-chart-dkt.svg"
},
{
"@type": "ImageObject",
"name": "The NINLARO combination had a 6-month improvement in PFS in comparison to the lenalidomide+dexamethasone combination.",
"contentUrl": "https://www.ninlaro.com/sites/default/files/2022-12/ninlaro-and-placebo-six-month-graph-dkt.svg"
}
],
"potentialAction": [
{
"@type": "ViewAction",
"name": "Get more info",
"url": "https://www.takedaoncologycopay.com/"
},
{
"@type": "ViewAction",
"name": "Discover side effects",
"url": "https://www.ninlaro.com/side-effects"
},
{
"@type": "ViewAction",
"name": "Find patient support",
"url": "https://www.ninlaro.com/financial-support"
}
],
"about": [
{
"@type": "Drug",
"name": "Ninlaro",
"nonProprietaryName": "ixazomib",
"offers": {
"@type": "Offer",
"price": "0",
"priceCurrency": "USD",
"url": "https://www.takedaoncologycopay.com"
},
"image": {
"@type": "ImageObject",
"name": "NINLARO® (ixazomib) logo",
"contentUrl": "https://www.ninlaro.com/images/ninlaro-ixazomib.png"
},
"prescribingInfo": "https://www.ninlaro.com/prescribing-information.pdf",
"mechanismOfAction": [
"Ixazomib is a reversible proteasome inhibitor. Ixazomib preferentially binds and inhibits the chymotrypsin-like activity of the beta 5 subunit of the 20S proteasome. Ixazomib induced apoptosis of multiple myeloma cell lines in vitro. Ixazomib demonstrated in vitro cytotoxicity against myeloma cells from patients who had relapsed after multiple prior therapies, including bortezomib, lenalidomide, and dexamethasone. The combination of ixazomib and lenalidomide demonstrated synergistic cytotoxic effects in multiple myeloma cell lines. In vivo, ixazomib demonstrated antitumor activity in a mouse multiple myeloma tumor xenograft model."
],
"warning": "[“NINLARO may cause serious side effects, including: Low platelet counts (thrombocytopenia) are common with NINLARO and can sometimes be serious. You may need platelet transfusions if your counts are too low. Tell your healthcare provider if you have any signs of low platelet counts, including bleeding and easy bruising. Stomach and intestinal (gastrointestinal) problems. Diarrhea, constipation, nausea, and vomiting are common with NINLARO and can sometimes be severe. Call your healthcare provider if you get any of these symptoms and they do not go away during treatment with NINLARO. Your healthcare provider may prescribe medicine to help treat your symptoms. Nerve problems are common with NINLARO and may also be severe. Tell your healthcare provider if you get any new or worsening symptoms including: tingling, numbness, pain, a burning feeling in your feet or hands, or weakness in your arms or legs. Swelling is common with NINLARO and can sometimes be severe. Tell your healthcare provider if you develop swelling in your face, arms, hands, legs, ankles, or feet, or if you gain weight from swelling. Skin reactions. Rashes are common with NINLARO. NINLARO can cause rashes and other skin reactions that can be serious and can lead to death. Tell your healthcare provider right away if you get a new or worsening rash, severe blistering or peeling of the skin, or mouth sores. Thrombotic microangiopathy (TMA). This is a condition involving blood clots and injury to small blood vessels that may cause harm to your kidneys, brain, and other organs, and may lead to death. Get medical help right away if you get any of the following signs or symptoms during treatment with NINLARO: fever, bruising, nose bleeds, tiredness, or decreased urination. Liver problems. Tell your healthcare provider if you get these signs of a liver problem: yellowing of your skin or the whites of your eyes; pain in your right upper stomach-area (abdomen).”,” Tell your healthcare provider if you get new or worsening signs or symptoms of the following during treatment with NINLARO: skin rash and pain (shingles) due to reactivation of the chicken pox virus (herpes zoster) OR blurred vision or other changes in your vision, dry eye, and pink eye (conjunctivitis)”,”Before taking NINLARO, tell your healthcare provider about all your medical conditions, including if you: have liver problems, have kidney problems or are on dialysis. Are pregnant or plan to become pregnant. NINLARO can harm your unborn baby. Females who are able to become pregnant: Avoid becoming pregnant during treatment with NINLARO. Your healthcare provider will do a pregnancy test before you start treatment with NINLARO. You should use effective non-hormonal birth control during treatment and for 90 days after your last dose of NINLARO. If using hormonal contraceptives (for example, birth control pills), you should also use an additional barrier method of contraception (for example, diaphragm or condom). Talk to your healthcare provider about birth control methods that may be right for you during this time. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with NINLARO. are breastfeeding or plan to breastfeed. It is not known if NINLARO passes into breast milk, if it affects an infant who is breastfed, or breast milk production. Do not breastfeed during treatment with NINLARO and for 90 days after your last dose of NINLARO. Males with female partners who are able to become pregnant: You should use effective birth control during treatment and for 90 days after your last dose of NINLARO. Tell your healthcare provider right away if your partner becomes pregnant or thinks she may be pregnant while you are being treated with NINLARO.”,” Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Talk to your healthcare provider before starting any new medicines during treatment with NINLARO.”,”Taking too much NINLARO (overdose) can cause serious side effects, including death. If you take more NINLARO than instructed by your healthcare provider, call your healthcare provider right away or go to the nearest hospital emergency room right away. Take your medicine pack with you.”]",
"manufacturer": {
"@type": "Corporation",
"name": "Takeda",
"logo": "https://www.ninlaro.com/sites/default/files/2023-02/logo-takeda.svg"
}
}
]
}
/how-it-works/
{
"@context": "http://schema.org",
"@type": "MedicalWebPage",
"audience": "https://health-lifesci.schema.org/Patient",
"specialty": "https://health-lifesci.schema.org/Oncologic",
"url": "https://www.ninlaro.com/how-it-works",
"headline": "How NINLARO® (ixazomib) Works For Relapsed Multiple Myeloma",
"description": "Discover how NINLARO®, a proteasome inhibitor, targets proteasomes to help destroy myeloma cells. See Important Safety Information and Prescribing Information.",
"speakable": [
{
"@type": "SpeakableSpecification",
"xpath": "/html/body/div[1]/main/div/article/div/div[2]/div/div[2]/div/p[1]/span"
}
],
"Video": {
"@type": "VideoObject",
"name": "How NINLARO works inside myeloma cells",
"description": "Learn how NINLARO specifically targets proteasomes to help destroy myeloma cells.",
"thumbnailUrl": "https://cf-images.us-east-1.prod.boltdns.net/v1/static/2574028764001/91a868ca-141d-472c-8f77-f1d2edff55ca/7e55f912-d516-479d-9ba1-1dc614019d78/1280x720/match/image.jpg",
"duration": "PT7M02S",
"contentUrl": "https://players.brightcove.net/2574028764001/SykGTiz2b_default/index.html?videoId=6316447334112",
"embedUrl": "https://players.brightcove.net/2574028764001/SykGTiz2b_default/index.html?videoId=6316447334112",
"transcript": "Multiple myeloma is a cancer of the bone marrow. Takeda has been engaged in the fight against Multiple Myeloma for nearly two decades. The disease is characterized by the abnormal growth of cells called plasma cells. Inside the cell, the proteasome is something that helps get rid of a build-up of proteins. Myeloma cells rely on the proteasome to survive. By targeting the proteasome, these therapies may be able to stop cell growth, and cause cell death. treatments that target the proteasome are c"
},
"image": {
"0": {
"@type": "ImageObject",
"name": "NINLARO® (ixazomib) logo",
"contentUrl": "https://ninlaro.com/themes/custom/tbsd_sub/logo.svg"
},
"1": {
"@type": "ImageObject",
"name": "Takeda logo.",
"contentUrl": "https://ninlaro.com/sites/default/files/2023-02/logo-takeda.svg"
},
"2": {
"@type": "ImageObject",
"name": "Key showing a multiple myeloma cell, protein, NINLARO, proteasome, and a digested protein.",
"contentUrl": "https://www.ninlaro.com/sites/default/files/styles/data_viz_desktop/public/2024-04/nin-how-it-works-key-dt.jpeg?itok=Ber4XviS"
},
"3": {
"@type": "ImageObject",
"name": "NINLARO in a myeloma cell.",
"contentUrl": "https://www.ninlaro.com/sites/default/files/styles/image_block_2/public/2022-12/myeloma-cell-image.jpg?itok=voVykCGj"
},
"4": {
"@type": "ImageObject",
"name": "Proteasome inhibition with NINLARO.",
"contentUrl": "https://www.ninlaro.com/sites/default/files/styles/image_block_2/public/2022-12/proteasome-inhibition-ninlaro-image.jpg?itok=4UiFIgGb"
},
"_items_truncated": true
},
"potentialAction": [
{
"@type": "ViewAction",
"name": "Study Results",
"url": "https://www.ninlaro.com/clinical-studies"
},
{
"@type": "ViewAction",
"name": "Get dosing schedule",
"url": "https://www.ninlaro.com/how-to-take"
}
],
"about": [
{
"@type": "Drug",
"name": "Ninlaro",
"nonProprietaryName": "ixazomib",
"offers": {
"@type": "Offer",
"price": "0",
"priceCurrency": "USD",
"url": "https://www.takedaoncologycopay.com"
},
"image": {
"@type": "ImageObject",
"name": "NINLARO® (ixazomib) logo",
"contentUrl": "https://www.ninlaro.com/images/ninlaro-ixazomib.png"
},
"prescribingInfo": "https://ninlaro.com/prescribing-information.pdf",
"mechanismOfAction": [
"Ixazomib is a reversible proteasome inhibitor. Ixazomib preferentially binds and inhibits the chymotrypsin-like activity of the beta 5 subunit of the 20S proteasome. Ixazomib induced apoptosis of multiple myeloma cell lines in vitro. Ixazomib demonstrated in vitro cytotoxicity against myeloma cells from patients who had relapsed after multiple prior therapies, including bortezomib, lenalidomide, and dexamethasone. The combination of ixazomib and lenalidomide demonstrated synergistic cytotoxic ef"
],
"warning": "[“NINLARO may cause serious side effects, including: Low platelet counts (thrombocytopenia) are common with NINLARO and can sometimes be serious. You may need platelet transfusions if your counts are too low. Tell your healthcare provider if you have any signs of low platelet counts, including bleeding and easy bruising. Stomach and intestinal (gastrointestinal) problems. Diarrhea, constipation, nausea, and vomiting are common with NINLARO and can sometimes be severe. Call your healthcare provid",
"manufacturer": {
"@type": "Corporation",
"name": "Takeda",
"logo": "https://www.ninlaro.com/sites/default/files/2023-02/logo-takeda.svg"
}
}
],
"_truncated": true,
"_original_size": 14772
}
/multiple-myeloma-relapse/
{
"@context": "http://schema.org",
"@type": "MedicalWebPage",
"audience": "https://health-lifesci.schema.org/Patient",
"specialty": "https://health-lifesci.schema.org/Oncologic",
"url": "https://www.ninlaro.com/multiple-myeloma-relapse",
"headline": "What Happens During a Multiple Myeloma Relapse?",
"description": "Multiple myeloma can return with or without symptoms. Discover the signs that multiple myeloma has returned, how to keep track of multiple myeloma, and what to do when it comes back.",
"speakable": [
{
"@type": "SpeakableSpecification",
"xpath": "/html/body/div[1]/main/div/article/div/div[2]/div/div[2]/div/p"
}
],
"potentialAction": [
{
"@type": "ViewAction",
"name": "Multiple Myeloma Relapse Guide for Ninlaro",
"url": "https://www.ninlaro.com/sites/default/files/resources/ninlaro-patient-relapse-brochure.pdf"
},
{
"@type": "ViewAction",
"name": "Understanding your Multiple Myeloma lab tests",
"url": "https://www.ninlaro.com/sites/default/files/2022-12/understanding_multiple_myeloma_lab_tests.pdf"
},
{
"@type": "ViewAction",
"name": "Look at Ninlaro study results",
"url": "https://www.ninlaro.com/clinical-studies"
},
{
"@type": "ViewAction",
"name": "Visit the lab test tracker",
"url": "https://www.ninlaro.com/lab-test-tracker"
},
{
"@type": "ViewAction",
"name": "Side effects of NINLARO",
"url": "https://www.ninlaro.com/side-effects"
}
],
"about": [
{
"@type": "Drug",
"name": "Ninlaro",
"nonProprietaryName": "ixazomib",
"offers": {
"@type": "Offer",
"price": "0",
"priceCurrency": "USD",
"url": "https://www.takedaoncologycopay.com"
},
"image": {
"@type": "ImageObject",
"name": "NINLARO® (ixazomib) logo",
"contentUrl": "https://www.ninlaro.com/images/ninlaro-ixazomib.png"
},
"prescribingInfo": "https://ninlaro.com/prescribing-information.pdf",
"mechanismOfAction": [
"Ixazomib is a reversible proteasome inhibitor. Ixazomib preferentially binds and inhibits the chymotrypsin-like activity of the beta 5 subunit of the 20S proteasome. Ixazomib induced apoptosis of multiple myeloma cell lines in vitro. Ixazomib demonstrated in vitro cytotoxicity against myeloma cells from patients who had relapsed after multiple prior therapies, including bortezomib, lenalidomide, and dexamethasone. The combination of ixazomib and lenalidomide demonstrated synergistic cytotoxic effects in multiple myeloma cell lines. In vivo, ixazomib demonstrated antitumor activity in a mouse multiple myeloma tumor xenograft model."
],
"warning": "[“NINLARO may cause serious side effects, including: Low platelet counts (thrombocytopenia) are common with NINLARO and can sometimes be serious. You may need platelet transfusions if your counts are too low. Tell your healthcare provider if you have any signs of low platelet counts, including bleeding and easy bruising. Stomach and intestinal (gastrointestinal) problems. Diarrhea, constipation, nausea, and vomiting are common with NINLARO and can sometimes be severe. Call your healthcare provider if you get any of these symptoms and they do not go away during treatment with NINLARO. Your healthcare provider may prescribe medicine to help treat your symptoms. Nerve problems are common with NINLARO and may also be severe. Tell your healthcare provider if you get any new or worsening symptoms including: tingling, numbness, pain, a burning feeling in your feet or hands, or weakness in your arms or legs. Swelling is common with NINLARO and can sometimes be severe. Tell your healthcare provider if you develop swelling in your face, arms, hands, legs, ankles, or feet, or if you gain weight from swelling. Skin reactions. Rashes are common with NINLARO. NINLARO can cause rashes and other skin reactions that can be serious and can lead to death. Tell your healthcare provider right away if you get a new or worsening rash, severe blistering or peeling of the skin, or mouth sores. Thrombotic microangiopathy (TMA). This is a condition involving blood clots and injury to small blood vessels that may cause harm to your kidneys, brain, and other organs, and may lead to death. Get medical help right away if you get any of the following signs or symptoms during treatment with NINLARO: fever, bruising, nose bleeds, tiredness, or decreased urination. Liver problems. Tell your healthcare provider if you get these signs of a liver problem: yellowing of your skin or the whites of your eyes; pain in your right upper stomach-area (abdomen).”,” Tell your healthcare provider if you get new or worsening signs or symptoms of the following during treatment with NINLARO: skin rash and pain (shingles) due to reactivation of the chicken pox virus (herpes zoster) OR blurred vision or other changes in your vision, dry eye, and pink eye (conjunctivitis)”,”Before taking NINLARO, tell your healthcare provider about all your medical conditions, including if you: have liver problems, have kidney problems or are on dialysis. Are pregnant or plan to become pregnant. NINLARO can harm your unborn baby. Females who are able to become pregnant: Avoid becoming pregnant during treatment with NINLARO. Your healthcare provider will do a pregnancy test before you start treatment with NINLARO. You should use effective non-hormonal birth control during treatment and for 90 days after your last dose of NINLARO. If using hormonal contraceptives (for example, birth control pills), you should also use an additional barrier method of contraception (for example, diaphragm or condom). Talk to your healthcare provider about birth control methods that may be right for you during this time. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with NINLARO. are breastfeeding or plan to breastfeed. It is not known if NINLARO passes into breast milk, if it affects an infant who is breastfed, or breast milk production. Do not breastfeed during treatment with NINLARO and for 90 days after your last dose of NINLARO. Males with female partners who are able to become pregnant: You should use effective birth control during treatment and for 90 days after your last dose of NINLARO. Tell your healthcare provider right away if your partner becomes pregnant or thinks she may be pregnant while you are being treated with NINLARO.”,” Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Talk to your healthcare provider before starting any new medicines during treatment with NINLARO.”,”Taking too much NINLARO (overdose) can cause serious side effects, including death. If you take more NINLARO than instructed by your healthcare provider, call your healthcare provider right away or go to the nearest hospital emergency room right away. Take your medicine pack with you.”]",
"manufacturer": {
"@type": "Corporation",
"name": "Takeda",
"logo": "https://www.ninlaro.com/sites/default/files/2023-02/logo-takeda.svg"
}
}
]
}
🛡️ Trust Signals — external proof links that back the declared identity
0Review mentions (all pages)
0External proof links (all pages)
| Page | Reviews | Proof links |
|---|---|---|
| / (home) | 0 | 0 |
| /clinical-studies/ | 0 | 0 |
| /how-it-works/ | 0 | 0 |
| /multiple-myeloma-relapse/ | 0 | 0 |
Explore the other reputation pillars for Takeda (NINLARO)
Analysis Disclosure & Source Attribution
This page presents a snapshot of public data from Takeda (NINLARO), captured on May 30, 2026, to show how machine logic reads Identity & Authority signals into an AI reputation evaluation.
Purpose: This data is presented under “Fair Use” for the purpose of independent signal analysis, allowing readers to see the raw signals behind the reputation score.
Notice to Takeda (NINLARO): This analysis is part of a non-adversarial audit conducted by 1 Euro SEO. The results are intended as professional feedback to help improve any website’s machine-readability and authority signals. The evaluation is free, and any company can request a fresh audit at any time.
Any company can use the insights for free and improve its voice. When a company has updated its content, it can always submit a new audit request, which will be reflected in a new current score.
To all users: You are encouraged to visit the live site at https://ninlaro.com to view the most current version of its content and see directly what this company is about and what it offers.